Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulations.

Citation data:

International journal of pharmaceutics, ISSN: 1873-3476, Vol: 486, Issue: 1-2, Page: 268-86

Publication Year:
2015
Usage 100
Abstract Views 82
Link-outs 18
Captures 86
Readers 83
Exports-Saves 3
Mentions 1
Blog Mentions 1
Social Media 4
Shares, Likes & Comments 4
Citations 42
Citation Indexes 42
PMID:
25827903
DOI:
10.1016/j.ijpharm.2015.03.053
Author(s):
B. Démuth; Z. K. Nagy; A. Balogh; T. Vigh; G. Marosi; G. Verreck; I. Van Assche; M. E. Brewster
Publisher(s):
Elsevier BV
Tags:
Pharmacology, Toxicology and Pharmaceutics
Most Recent Blog Mention
review description
Application of amorphous solid dispersions (ASDs) is considered one of the most promising approaches to increase the dissolution rate and extent of bioavailability of poorly water soluble drugs. Such intervention is often required for new drug candidates in that enablement, bioavailability is not sufficient to generate a useful product. Importantly, tableting of ASDs is often complicated by a number of pharmaceutical and technological challenges including poor flowability and compressibility of the powders, compression-induced phase changes or phase separation and slow disintegration due to the formation of a gelling polymer network (GPN). The design principles of an ASD-based system include its ability to generate supersaturated systems of the drug of interest during dissolution. These metastable solutions can be prone to precipitation and crystallization reducing the biopharmaceutical performance of the dosage form. The main aim of the research in this area is to maintain the supersaturated state and optimally enhance bioavailability, meaning that crystallization should be delayed or inhibited during dissolution, as well as in solid phase (e.g., during manufacturing and storage). Based on the expanding use of ASD technology as well as their downstream processing, there is an acute need to summarize the results achieved to this point to better understand progress and future risks. The aim of this review is to focus on the conversion of ASDs into tablets highlighting results from various viewpoints.